Are the adverse effects of glitazones linked to induced testosterone deficiency?

Carruthers, M.; Trinick, T.R.; Jankowska, E.; Traish, A.M.
January 2008
Cardiovascular Diabetology;2008, Vol. 7, p1
Academic Journal
Background: Adverse side-effects of the glitazones have been frequently reported in both clinical and animal studies, especially with rosiglitazone (RGZ) and pioglitazone (PGZ), including congestive heart failure, osteoporosis, weight gain, oedema and anaemia. These led to consideration of an evidence-based hypothesis which would explain these diverse effects, and further suggested novel approaches by which this hypothesis could be tested. Presentation of hypothesis: The literature on the clinical, metabolic and endocrine effects of glitazones in relation to the reported actions of testosterone in diabetes, metabolic syndrome, and cardiovascular disease is reviewed, and the following unifying hypothesis advanced: "Glitazones induce androgen deficiency in patients with Type 2 Diabetes Mellitus resulting in pathophysiological changes in multiple tissues and organs which may explain their observed clinical adverse effects." This also provides further evidence for the lipocentric concept of diabetes and its clinical implications. Testing of the hypothesis: Clinical studies to investigate the endocrine profiles, including measurements of TT, DHT, SHBG, FT and estradiol, together with LH and FSH, in both men and women with T2DM before and after RGZ and PGZ treatment in placebo controlled groups, are necessary to provide data to substantiate this hypothesis. Also, studies on T treatment in diabetic men would further establish if the adverse effects of glitazones could be reversed or ameliorated by androgen therapy. Basic sciences investigations on the inhibition of androgen biosynthesis by glitazones are also warranted. Implications of the hypothesis: Glitazones reduce androgen biosynthesis, increase their binding to SHBG, and attenuate androgen receptor activation, thus reducing the physiological actions of testosterone, causing relative and absolute androgen deficiency. This hypothesis explains the adverse effects of glitazones on the heart and other organs resulting from reversal of the action of androgens in directing the maturation of stem cells towards muscle, vascular endothelium, erythroid stem cells and osteoblasts, and away from adipocyte differentiation. The higher incidence of side-effects with RGZ than PGZ, may be explained by a detailed study of the mechanism by which glitazones down-regulate androgen biosynthesis and action, resulting in a state of androgen deficiency.


Related Articles

  • cyclopenthiazide. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p208 

    A definition of the term "cyclopenthiazide" is presented. It refers to a thiazide diuretic drug used to reduce oedema associated with heart failure, kidney disorders, cirrhosis of the liver and to treat hypertension. Side effects of cyclopenthiazide include lethargy, loss of appetite, leg...

  • Testosterone Trial Halted.  // JAMA: Journal of the American Medical Association;8/25/2010, Vol. 304 Issue 8, p846 

    The article reports on the decision of a data and safety monitoring board (DSMB) to stop the treatment phase of a clinical trial of testosterone therapy following the identification of adverse cardiovascular effects in the treatment group.

  • Safety of Testosterone Replacement Therapy. Abramowicz, Mark; Zuccotti, Gianna; Pflomm, Jean-Marie // JAMA: Journal of the American Medical Association;4/12/2016, Vol. 315 Issue 14, p1512 

    The article focuses on the safety and effectiveness of the testosterone replacement therapy. Topics mentioned include the placebo-controlled clinical trials, the pulmonary oil microembolism (POME), the side effects of the testosterone replacement therapy, and the effects of the therapy to...

  • Icatibant.  // Reactions Weekly;3/22/2008, Issue 1194/1195, p21 

    The article describes a case of icatibant-induced transient local erythema and wheal. It references a study by R. Levy and colleagues, published in a 2007 issue of "Allergy." The patient participated in a clinical trial of icatibant indicated for hereditary angioedema. The adverse reactions...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk. Elliott, William T. // Clinical Cardiology Alert;Jul2007 Pharmacology Watch, p1 

    The article reports on a black box warning that will be receive by GlaxoSmithKline's rosiglitazone (Avandia) from the U.S. Food & Drug Administration (FDA) because of concerns over heart failure associated with use of the drug. The other drug that will be subjected to a black box warning is...

  • Treatment of Heart Failure with Spironolactone – Trial and Tribulations. McMurray, John J.V.; O'Meara, Eileen // New England Journal of Medicine;8/5/2004, Vol. 351 Issue 6, p526 

    The article presents an editorial regarding a clinical trial by Juurlink and colleagues in this issue of the journal, titled the Randomized Aldactone Evaluation Study (RALES), which looked at the treatment of heart failure with spironolactone. The clinical trial showed a low incidence of adverse...

  • Rosiglitazone and Cardiotoxicity � Weighing the Evidence. Nathan, David M. // New England Journal of Medicine;7/5/2007, Vol. 357 Issue 1, p64 

    This editorial comments on the evidence presented from the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. This study was specifically designed to measure the effects on cardiovascular outcome of treatment with rosiglitazone. The study does...

  • Pergolide associated with cardiac valvulopathy and CHF.  // Reactions Weekly;7/5/2008, Issue 1209, p4 

    The article discusses research being done on pergolide. It references a study by C. Zadikoff et al, published in a May 2008 issue of the "Canadian Journal of Neurological Sciences." Results of a retrospective, population-based cohort study showed that the use of pergolide is linked with cardiac...

  • Acute heart failure - prognostic factors during admission - observational study. Grigorică, Lucica; Macarie, C. // Romanian Journal of Cardiology;2012, Vol. 22 Issue 3, p177 

    Acute heart failure has become a real public health issue in the USA, as well as in many European countries. Mortality rates during hospitalization remain high. Clinical trials have yet to prove their efficiency in generating therapies capable of improving survival rates. The authors of this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics